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The intestinal tract represents the largest interface between the external environment 
and the human body. Nutrient uptake mostly happens in the intestinal tract, where the 
epithelial surface is constantly exposed to dietary antigens. Since inflammatory response 
toward these antigens may be deleterious for the host, a plethora of protective mecha-
nisms take place to avoid or attenuate local damage. For instance, the intestinal barrier 
is able to elicit a dynamic response that either promotes or impairs luminal antigens 
adhesion and crossing. Regulation of intestinal barrier is crucial to control intestinal 
permeability whose increase is associated with chronic inflammatory conditions. The 
cross talk among bacteria, immune, and dietary factors is able to modulate the mucosal 
barrier function, as well as the intestinal permeability. Several nutritional products have 
recently been proposed as regulators of the epithelial barrier, even if their effects are in 
part contradictory. At the same time, the metabolic function of the microbiota generates 
new products with different effects based on the dietary content. Besides conventional 
treatments, novel therapies based on complementary nutrients are now growing. Fecal 
therapy has been recently used for the clinical treatment of refractory Clostridium difficile 
infection instead of the classical antibiotic therapy. In the present review, we will outline the 
epithelial response to nutritional components derived from dietary intake and microbial 
fermentation focusing on the consequent effects on the integrity of the epithelial barrier.
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iNTRODUCTiON
The intestinal tract is the largest interface between the body and the external environment repre-
sented by the intestinal lumen (1). The structure of the intestinal wall consists of a mucosa that is 
highly specialized in each part of the intestinal tract. In the small and large intestine, the mucosa 
consists of a single monolayer of epithelial cells critical to both absorb nutrients and avoid the entry 
of potentially harmful entities, including microorganisms or dietary antigens (2). To concomitantly 
fulfill both functions, the intestinal barrier permeability is regulated by a dynamic process. The entry 
of small amounts of nutritional antigens and microorganisms can occur even without a pathogenic 
response. This event induces a homeostatic immune response characterized by immune tolerance to 
these antigens (3). Intestinal barrier damage can be primarily due to an enhancement of the paracel-
lular permeability associated with an increased permeation of luminal antigens. These events in turn 


















































FiGURe 1 | Structure of intestinal barrier. The intestinal barrier is a complex entity, which is composed of cellular and extracellular elements. The cellular part is 
defined by intestinal epithelium (five distinct type of cells, such as stem cells, Paneth cells, enterocytes, goblet cells, and enteroendocrine cells) and the underlying 
lamina propria, which contains DCs (also intraepithelial DCs, IEDCs), macrophages, intraepithelial lymphocytes (IEL), T regulatory cells (T Regs), TCD4+ lymphocytes 
(T CD4), B lymphocytes (B), and plasma cells (PCs). The extracellular component consists in a mucus layer produced by Globet cells, AMPs secreted by Paneth 
cells, and sIgA dimers released by plasma cells. DCs, dendritic cells; AMPs, antimicrobial peptides; sIgA, secretory ImmunoglobulinA.
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damage (4). Intestinal permeability is a dynamic process whose 
regulation is determined by the interaction among several players, 
including barrier constituents, immune cells, microbiota, and also 
external factors, such as the diet. Alterations of mucosal barrier 
function are increasingly linked to a broad spectrum of pathologies 
(5–7), including intestinal disorders such as inflammatory bowel 
disease (IBD) (8). For this reason, a deeper understanding of the 
multiple mechanisms involved in the regulation of the mucosal 
barrier is needed. The main focus of this review is to summarize 
how nutrition can influence the intestinal barrier function.
THe iNTeSTiNAL BARRieR
The intestinal barrier is an heterogeneous entity that is composed 
of cellular and extracellular components (9). The cellular part is 
defined by the intestinal epithelium and the underlying lamina 
propria. The intestinal epithelium contains five distinct types of 
cells: stem cells with interposed Paneth cells producing antimi-
crobial peptides (AMPs), absorptive enterocytes, mucus secreting 
goblet cells, and hormone producing enteroendocrine cells (10). 
Lamina propria contains dendritic cells (DCs), intraepithelial 
DCs (IEDCs), macrophages, intraepithelial lymphocytes (IEL), 
T regulatory cells (T Regs), TCD4+ lymphocytes, B lymphocytes, 
and plasma cells (11, 12). The extracellular component of the bar-
rier is represented by the mucus layer secreted by goblet cells. The 
mucus is crucial to facilitate food passage, to protect the epithelial 
cells from the action of digestive enzymes present in the lumen, 
and to avoid the firm adhesion of bacteria to the epithelial cells, 
thus preventing their entry into the lamina propria (13). This 
function is implemented by AMPs and secretory (s) IgA dimers 
released by plasma cells (14) (Figure 1).
The intestinal barrier integrity is essential for the intestinal 
permeability; specifically, intestinal epithelial cells (IECs) have 
a major role in this context (15, 16). The epithelial monolayer 
represents a physical barrier due to the fact that in the absence 
of specific transporters the plasma membrane of these cells 
is impermeable to the majority of hydrophilic solutes (9). 
Epithelial cells are held together by the apical junctional com-
plexes, consisting of adherent junctions and tight junctions 
(TJs), as well as by underlying desmosomes (17). Adherent 
junctions and desmosomes are a site of intercellular com-
munication that close together adjacent IECs providing strong 
bonds between them without altering paracellular permeability 
as in the case of TJs. TJs are composed of four transmembrane 
(TM) proteins: such as claudins (18), occludin (19), junctional 
adhesion molecules (JAMs) (20), and tricellulin (21), and 
some cytosolic scaffold proteins, such as zonulae occludens 
(ZO) and cingulin (22, 23). The extracellular domains of the 
TM proteins form a selective barrier through both homophilic 
and heterophilic interactions with nearby cells. Conversely, 
the intracellular domains of TM proteins are linked to the 
perijunctional actomyosin ring by the interaction with cytosolic 
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scaffold proteins (24). This interaction permits the cytoskeletal 
regulation of TJ-mediated barrier integrity (17). TJs are also 
important in determining the charge selectivity of the paracel-
lular pathway (25). Specifically, this effect is exerts by claudins 
(26). In fact, in the intestine, claudin-2 forms cation-selective 
channels in TJs (27). TJs are highly regulated at transcriptional 
and post-transcriptional levels by physiological or pathophysi-
ological stimuli (9); among these, an important role has been 
attributed to nutrients, as discussed below.
iNTeSTiNAL PeRMeABiLiTY AND 
TRANSPORT PATHwAYS
Intestinal permeability is an intrinsic property of the intestine 
that is defined as “the facility with which intestinal epithelium 
allows molecules to pass through by non-mediated passive diffu-
sion” (28). The transport of molecules from the intestinal lumen 
to the lamina propria can occur through two different pathways: 
the paracellular diffusion of small molecules by TJs and the tran-
scellular transport through transcytosis (endocytosis/exocytosis) 
of large molecules mediated or not by membrane receptors (29). 
Both pathways allow luminal antigens to gain access to the sub-
epithelial compartment and to interact with local immune cells.
Paracellular permeability is mainly determined by pore size in 
TJs, determining a high-capacity pathway that is size-restricted 
and a low-capacity pathway, independent of size. The latter can 
be due to transient (e.g., apoptosis) or fixed breaks (different 
TJ proteins) in the epithelial cells (29). In fact, small and large 
pores are defined by different TJ proteins, such as claudins (30, 
31) and tricellulin (17), respectively. The paracellular diffusion of 
small molecules through TJ pores is driven by water movement 
in response to electrochemical or osmotic gradients across the 
epithelium (29).
Transcellular transport pathways can be mediated by dif-
ferent type of cells; M cells overlying Payer’s patches (PPs) and 
isolated lymphoid follicles (32), DCs (33–35), goblet cells (36), 
and columnar enterocytes. Enterocytes sample molecules of 
high molecular weight, such as food antigens, by endocytosis 
at the apical membrane and transcytosis toward the lamina 
propria (37, 38). During transcytosis, full-length proteins are 
degraded in acidic and lysosomal compartments of entero-
cytes and released at the basolateral membrane as amino 
acids when totally degraded or as immunogenic peptides if 
partially degraded (39). Immunogenic peptides released into 
the lamina propria can be taken up by local antigen-presenting 
cells (APCs) and activate the immune response (40); alterna-
tively, they can be transported into the draining lymph nodes 
by lacteals (41). The presence of food antigens in the form of 
small immunogenic peptides suggests that during transcytosis, 
a mechanism that avoids their total degradation might occur 
(42). This could be due to exosome-like structures produced 
by IECs. Exosomes are small membrane vesicles (~80 nm in 
diameter) resulting from inward membrane invagination of 
the MHC class II-enriched compartments in which luminal 
antigens arrived after endosomal degradation (43). These com-
partments can both lead to lysosomes or fuse with the plasma 
membrane. Exosomes released outside the cells interact with 
local immune cells (44). Exosome-bound peptides are more 
efficient in interacting with DCs and promoting antigen pres-
entation to T cells than free peptides (45). Also, in humans, it 
was demonstrated that HLA-DR/peptide complexes bound to 
exosome-like vesicles were highly immunogenic (46).
The transcytosis of food antigens occurs primarily by a 
fluid-phase endocytosis of proteins at the apical membrane of 
enterocytes (29). However, the access of luminal antigens into 
the intestinal mucosa is also possible thanks to the expression of 
immunoglobulin receptors (IgR) expressed on the apical surface 
of enterocytes (47). After the binding to IgRs, luminal antigens 
cross the barrier in the form of immune complexes (ICs) 
(29). IgA is the most representative Ig isotype at the mucosal 
interface, and it is secreted in the intestinal lumen through 
polymeric IgR (pIgR) in the dimeric form of sIgA (48). sIgA 
represents one of the mechanisms exerted by intestinal barrier 
to control the interaction of microbial and food antigens with 
the intestinal lumen (29). Despite the usual basal-to-apical 
secretion pathway of the sIgA (48), in some pathological condi-
tions, an abnormal retro-transport of sIgA ICs can allow the 
entry of luminal antigens in the intestinal mucosa (29). The 
IgA-mediated retro-transport of pathogenic bacteria is benefi-
cial for bacterial clearance and intestinal homeostasis (49). The 
same mechanism applied to non-pathogenic antigens, such as 
food antigens, could be deleterious rather than protective (48). 
One of the most common examples of the aforementioned 
mechanism is celiac disease (CD), an enteropathy induced by 
the abnormal activation of T cells by gluten-derived gliadin 
peptides (50). The high proline content of gliadin prevents their 
efficient digestion and leads to the release of large immunogenic 
peptides that cause CD (51). The ectopic expression of the 
transferrin receptor CD71 at the apical surface of IECs of CD 
patients allows the retro-transport of sIgA/gliadin IC into the 
lamina propria (29). On the contrary, in healthy individuals, 
CD71 is expressed on basolateral membrane of IECs and this 
permits gliadin peptides to be almost totally degraded (52). 
Also, IgEs are involved in transcytosis of food antigens due 
to the expression of their receptor, CD23, at the apical side 
of enterocytes (53). Increased expression of this receptor can 
drive the transport of IgEs/allergen ICs from the intestinal 
lumen to the lamina propria causing mast cell degranulation 
and allergic inflammatory reactions (54).
ReGULATiON OF THe iNTeSTiNAL 
BARRieR FUNCTiON BY NUTRiTiONAL 
MeANS
Food is not only a source of nutrients but may also modulate 
some physiological functions of the body. This is especially true 
for the intestinal tract because of the continuous interaction of 
the intestine with dietary antigens (55). Recent studies demon-
strated the effects of the interaction between food and IECs. In 
fact, dietary antigens are able to modulate transporter activity, TJ 
permeability, metabolic enzyme expression, immune functions, 
and microbiota (56).
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Food Regulation of Transporters and ion 
Channel Function
Absorption of nutrients is mainly located in the small intestine, 
while maintenance of fluid-ion homeostasis mostly happens in 
the large intestine. This process is regulated by transporters and 
ion channels localized on the enterocytes membrane.
Glucose absorption in the small intestine is strictly regulated 
by glucose transporters in IECs that are distinguished as sodium 
dependent (SGLT1) and sodium independent (GLUT2, 3, 5) 
(57). The inhibition of these transporters is induced by some 
food derivates, such as polyphenolic compounds [tannic acid, 
chlorogenic acid, catechins, in particular, epigallocatechin gallate 
(EGCG)] (58, 59) and gymnemic acid, a taste-modulating triter-
pene glucoside extracted from the leaves of Gymnema sylvestre 
(60). Also, calcium uptake by specific transporters located on the 
IECs is regulated by diet compounds (61). For example, enhanced 
calcium uptake is observed with whey protein digest though the 
mechanism is not defined at all (62).
Furthermore, most of the ion channels present in epithelial 
cells are regulated by the levels of cyclic nucleotides, especially 
cAMP. Food indirectly regulates the levels of cAMP by augment-
ing the secretion of some hormones (63, 64), such as guanylin 
and natriuretic peptides, that increase cAMP levels. cAMP can 
directly bind to cyclic nucleotide-gated ion channels (CNG chan-
nels) and induce the influx of calcium ions into the cells (65). 
It can also inhibit the activity of sodium–hydrogen exchanger3 
(NHE3), thus preventing the absorption of sodium ions, chloride 
ions, and water by the epithelium (66–68).
Food Regulation of TJ Permeability
Tight junctions are not static but highly dynamic structures con-
stantly shaped due to interactions with internal/external stimuli, 
such as cytokines, growth factors, food residues, and pathogenic 
and commensal bacteria (56).
Food substances can act by increasing or decreasing TJ per-
meability, as described in Figure 2 and summarized in Table 1. 
One of the most common parameters to evaluate the intestinal 
permeability, as will be described later, is transepithelial electrical 
resistance (TER) that measure paracellular ions flux (69). Among 
the food-derived compounds able to modulate the intestinal 
barrier function, there are some amino acids. Glutamine (Gln) 
represents the primary source of amino acids for the intestinal 
mucosa (17). It was demonstrated that Gln improves intestinal 
barrier function in highly stressed patients (70) and in animal 
models of endotoxin-induced permeability (71). Also, Gln can 
restore stress-induced loss of barrier integrity by increasing TER 
(72). The increase in permeability was confirmed in another work 
in which Caco-2 cells were deprived of Gln by a combination of a 
Gln-free media and the inhibition of Gln synthetase (73).
The barrier impairment is caused by the perturbation of TJ 
protein (ZO-1, occludin, and claudin-1) expression and distribu-
tion. These mechanisms are mediated by the PI3K/Akt pathway 
since the genetic knockdown or pharmacological inhibition of 
PI3K is able to neutralize TER reduction induced by Gln depriva-
tion (74). Furthermore, Gln can also prevent the negative effects 
of acetaldehyde, an oxidized metabolite of ethanol, avoiding the 
redistribution of ZO-1 and occludin. This action requires the 
activation of EGF receptor (75). Another amino acid, tryptophan 
(Trp), reduces intestinal permeability by increasing TER in 
Caco-2 cells in a dose-dependent manner even if the molecular 
mechanism is not yet known (76). Furthermore, peptides derived 
from cheese and milk proteins have been shown to suppress 
intestinal permeability. β-casein peptide increases both occludin 
expression and TER in Caco-2 (77), while β-lactoglobulin induces 
an increase in TER likely due to changes into the cytoskeletal 
structure. In fact, treatment of cells with cytochalasin D (able 
to disrupt the cytoskeleton) inhibits TER increase induced by 
β-lactoglobulin (78).
Also, some vitamins show protective effects on intestinal 
permeability. For example, vitamin D enhances the expression 
of TJ (ZO-1 and claudin-1) and adherent junction (E-cadherin) 
proteins (79). Vitamin D is also able to prevent dextran sodium 
sulfate (DSS)-induced decrease in TER both in vitro and in vivo 
models in a vitamin D receptor (VDR)-dependent manner (79). 
In fact, VDR knockout mice exhibits more severe colitis as com-
pared to wild-type mice due to earlier intestinal barrier defects 
than wild-type mice, as indicated by TER and TJ proteins expres-
sion. Retinol, an alcohol form of vitamin A, partially attenuates 
the decreases in TER induced by Clostridium difficile toxin A in 
intestinal Caco-2 cells (80). However, the underlying mechanism 
remains to be elucidated.
Polyphenols participate in the regulation of the intestinal 
barrier too. The flavonoid subgroup, quercetin, myricetin, and 
kaempferol, enhances barrier integrity in intestinal Caco-2 cells 
(17). Quercetin, the most common flavonoid in nature, increases 
TER and reduces paracellular flux across Caco-2 monolayers in 
a dose-dependent manner (81, 82). This mechanism is accompa-
nied by an increase in claudin-4 expression and the assembly of 
ZO-2, occludin, and claudin-1 at the TJ level. Also, kaempferol 
increases TER due to promotion of the cytoskeletal association 
of ZO-1, ZO-2, occludin, claudin-1, claudin-3, and claudin-4 and 
an increase in the expression of some TJ proteins (83). The isofla-
vonoid genistein inhibits the redistribution and the dissociation 
of occludin/ZO-1 complex protecting barrier integrity against 
acetaldehyde and oxidative stress (84, 85).
On the contrary, other food compounds negatively regulate 
intestinal barrier, e.g., gliadin whose effect correlates with CD 
(86), as previously discussed. Gliadin binds to CXCR3 on IECs and 
increases intestinal permeability by a MyD88-dependent release 
of zonulin (87). Zonulin interacts with a specific surface receptor 
activating phospholipase C that hydrolyzes phosphatidyl inositol 
releasing inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG) (88). DAG and PPI-3 can directly and indirectly (through 
the release of intracellular Ca2+), respectively, activate protein 
kinase C (PKC). Activated PKC catalyzes the phosphorylation 
of target proteins with subsequent polymerization of soluble 
G-actin in F-actin. This polymerization causes the rearrangement 
of the filaments of actin and the subsequent displacement of pro-
teins, including ZO-1 from the junctional complex. As a result, 
intestinal TJs become looser allowing the paracellular passage 
of gliadin from the intestinal lumen to the lamina propria (89). 
Ex vivo experiments on C57BL6 and CXCR3−/− mice confirmed 
these observations. Intestinal segments exposed to gliadin from 










FiGURe 2 | Tight Junction regulation by food antigens. (A) TJs are composed of some transmembrane proteins [occludin, claudins, and junctional adhesion 
molecules (JAMs)] and cytosolic scaffold proteins [zonulae occludens (ZO) and cingulin]. The extracellular domains of transmembrane proteins of adjacent IECs 
interact to form the selective intestinal barrier, while cytosolic scaffolds anchor the transmembrane proteins to the actomyosin ring. (B) The intake of some food 
antigens, such as gliadin, fatty acids, or ethanol, can directly increase intestinal permeability by different mechanisms (1–7); (1) alteration in cellular distribution of 
occludin proteins, (2) reduction in the cellular content of occludins, (3) alteration in cellular distribution of claudin, (4) inhibition of protein tyrosine phosphatase (PTP) 
activity that induce tyrosine phosphorylation of ZO-1 and occludin and their dissociation from the junctional complex, (5) activation of PKC that leads to 
polymerization of actin and subsequent displacement of TJ proteins, including ZO-1, (6) displacement of ZO proteins from the junctional complexes, (7) activation of 
MLCK activity. (C) Other dietary antigens, such as amino acid, milk and cheese peptides, vitamins, and polyphenols, have the ability to decrease intestinal 
permeability through distinct pathways; (1–3) increase in the cellular content of occludin, claudin, and ZO proteins, respectively, (4) restoration of ZO-1/occludin 
assembly, (5) inhibition of MLCK activation. PKC, protein kinase C; MLC, myosin light-chain; MLCK, myosin light-chain kinase; TK, tyrosine kinase.
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wild-type but not from CXCR3−/− mice increase zonulin release 
and intestinal permeability (87). Furthermore, it has recently 
been demonstrated by in vivo intravital microscopy that gliadin 
modulates intestinal permeability inducing a redistribution of 
ZO-1 (90).
Middle-chain fatty acids (MCFAs), e.g., capric acid and lauric 
acid and long-chain fatty acids [LCFAs, e.g., eicosapentaenoic 
acid (EPA), γ-linoleic acid, and docosahexaenoic acid (DHA)] 
are also able to increase TJ permeability by reducing TER (91, 
92). The barrier properties of the latter are controversial since it 
was discovered that, unlike the finding in Caco2 cell monolayer, 
EPA and DHA were particularly effective in supporting barrier 
integrity. In a different cell line (T84 cell), administration of 
EPA and DHA improves resistance and reduces IL-4-mediated 
permeability (93). Capric acid, but not lauric acid, induced 
the redistribution of TJ proteins (occludin and ZO-1) and the 
rearrangement of the cytoskeleton actin (94). This means that 
these two MCFAs act with a different mechanism (95). The 
common ground is the paracellular permeability induced by 
both acids that requires intracellular Ca2+-dependent myosin 
light chain kinase (MLCK) activation (95). Short-chain fatty 
acids (SCFAs) also modulate intestinal barrier. The SCFAs, 
such as acetate, propionate, and butyrate, are the major anions 
in the colon and are mainly produced by bacterial fermenta-
tion of undigested carbohydrates. Butyrate strengthens the 
barrier through the increase among TER, ZO-1/ZO-2, and 
TABLe 1 | effect of diet-derived compounds on intestinal permeability.




Mechanisms of action Models of study Reference
AMiNO ACiDS
Gln Decreased Increased Unknown Caco2 cell line (66)
Gln deprivation Increased Not determined Reduction of occludin, claudin-1, and ZO-1/
redistribution of claudin-1 and occludin
Caco2 cell line (67)
Trp Decreased Increased Unknown Caco2 cell line (70)
PePTiDeS
β-casein Decreased Increased Increase occludin expression Caco2 cell line (71)
β-lactoglobulin Decreased Increased Modifications into the cytoskeletal structure Caco2 cell line (72)
viTAMiNS
Vitamin D Decreased Increased (in 
Caco2 cell line)
Enhancement of claudin-1, ZO-1 and E-cadherin 
proteins expression
SW480-Caco2 cell lines/VDR+/+ and 
VDR−/− in C57BL6 background
(73)
Retinol (vitamin A) Decreased Increased Neutralization Clostridium difficile toxin A Caco2 cell line (74)
POLYPHeNOLS
Quercetin Decreased Increased Increase in claudin-4 expression and in ZO-2, 
occludin and claudin-1 assembly
Caco2 cell line (75, 76)
Kaempferol Decreased Increased Promotion of ZO-1/2, occludin and claudin-1/3/4 
cytoskeletal association
Caco2 cell line (77)
Genistein Decreased Increased Inhibition of the redistribution and the dissociation of 
occludin/ZO-1 complex
Caco2 cell line (78, 79)
Decreased Increased Inhibition of TNFα-mediated effects HT-29/B6 cell line (99)
EGCG Decreased Increased Inhibition of INFγ-mediated effects T84 cell line (98)
Curcumin Decreased Increased Inhibition of TNFα- and IL-1β-mediated effects Caco2 cell line (100, 101)
DiTeRPeNe GLYCOSiDe
Capsianoside Increased Decreased Changes in F/G actin ratio Caco2 cell line (92)
LCFAs
EPA and DHA Increased Decreased Protein kinase C regulation/unknown Caco2 cell line (84, 85)
Decreased Increased Reduction of IL-4-mediated permeability T84 cell line (86)
MCFA
Capric acid Increased Decreased Redistribution of occludin and ZO-1/MLCK activation Caco2 cell line (87)




Decreased Increased Activation of PI3K Caco2/T84 cell lines (90)
MiNeRALS
Zinc depletion Increased Decreased Redistribution of occludin, ZO-1, E-cadherin, and 
β-catenin and F-actin
Caco2 cell line (93)
ALCOHOLS
Ethanol Increased Decreased Redistribution of occludin and ZO1/MLCK activation Caco2 cell line (94)
Acetaldehyde Increased Decreased Loss of interaction between occludin/ZO-1 and 
β-catenin/E-cadherin by a tyrosine phosphorylation-
dependent mechanism
Caco2 cell line/Sprague-Dawley  
rats and C3H/He mice
(79, 95–97)
Chitosan Increased Decreased Redistribution of ZO-1 and F-actin distribution Caco2 cell line  (91)
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cingulin protein in rat-1 fibroblasts (96). Acetic and propionic 
acids from diet increased TER and decreased permeability to 
lucifer yellow in a dose-dependent manner in the rat colon 
and intestinal cells (97). The acetic acid-mediated increase in 
TER could be suppressed by the pharmacological inhibition of 
PI3K (97).
Apart from fatty acids, there are other food compounds that 
negatively regulate barrier function. Chitosan, a polysaccharide 
widely used in the food industry, is able to increase paracellular 
permeability by altering the distribution of ZO-1 and F-actin 
(98). Moreover, sweet pepper extract decreases TER, and this 
effect is likely mediated by capsianoside, its active compound, 
that induces dysfunctional TJs by changing the F-actin and 
G-actin ratio (99).
Zinc is essential for the survival and function of the cells and its 
depletion increases intestinal permeability by reducing TER and 
altering the expression of ZO-1, occludin, and F-actin filaments 
(100). Alcohol and its oxidized metabolite, acetaldehyde, impair 
intestinal barrier function. Ethanol decreases TER and increases 
mannitol flux due to a redistribution of ZO-1 and occludin (101) 
and barrier impairment seems to be caused by a MLCK-dependent 
mechanism. Administration of acetaldehyde in  vivo induces an 
impairment of barrier integrity, as indicated by TER decrease and 
improved dextran permeability (102). In vitro studies show that 
the underling mechanism acts via a tyrosine kinase-dependent 
mechanism (85, 103). The suppression of protein tyrosine phos-
phatase (PTP) activity by acetaldehyde causes tyrosine phospho-
rylation of ZO-1, occludin, E-cadherin, and β-catenin and their 
December 2015 | Volume 6 | Article 6127
De Santis et al. Diet Modulation of Intestinal Permeability
Frontiers in Immunology | www.frontiersin.org
dissociation from the respective TJ and AJ complexes, finally 
leading to increased paracellular permeability (85, 104).
Food components can regulate TJ permeability not only directly 
by targeting signal transduction pathways involved in TJ regula-
tion but also indirectly by influencing cytokine signaling involved 
in this modulation (17). For example, epigallocatechin-3-gallate 
(EGCG), the predominant polyphenol in green tea, does not affect 
epithelial permeability when administered alone to confluent T84 
cells (105). On the contrary, the administration of this polyphenol 
in combination with IFNγ prevents the negative effects of this 
cytokine on epithelial permeability (105). Furthermore, genistein 
inhibits the tumor necrosis factor α (TNFα)-mediated TER 
reduction in HT-29/B6 cells (106). Finally, it was demonstrated 
that another polyphenol, curcumin, is able to block TNFα- and 
inteleukin-1β (IL-1β)-induced NF-κB activation, increasing TER 
and reducing intestinal permeability (107, 108).
Food Regulation of intestinal 
Detoxification Systems
Detoxification systems in IECs are activated after the binding of 
xenobiotic to intracellular receptors [e.g., the arylhydrocarbon 
receptor (AhR) and the pregnant X receptor (PXR)] and the 
subsequent entry into the nucleus that induce the expression of 
some detoxification enzymes (109). These enzymes are involved 
in the oxidation and conjugation of xenobiotics. They are also 
involved in the excretion of harmful compounds from the cells 
(110). It was demonstrated that some flavonoids and terpenoids 
are able to induce PXR-dependent transcriptional activity activat-
ing the intestinal detoxification system (111). Moreover, dietary 
flavonoids can help to balance the ratio between activation and 
suppression of detoxification enzymes to avoid the possibility that 
a helpful mechanism could become detrimental by reducing the 
bioavailability of drugs and functional foods (56).
Food Regulation by Microbiota
The microbiota is involved in several functions crucial for the host 
homeostasis. These include metabolic homeostasis and cross talk 
with the immune system. The metabolic function is fundamental, 
as the bacterial degradation of some complex nutrients from food 
is the source of essential amino acids and vitamins (112). In fact, 
human enzymes cannot degrade the most complex carbohy-
drates and plant polysaccharides (113). Among the metabolites 
produced during the process, there are some essential products 
absorbed by the host. These include vitamins, such as vitamin K, 
and most of the water-soluble B vitamins, such as biotin, cobala-
min, and riboflavin (114, 115). Furthermore, other metabolites 
produced by microbiota are the SCFAs (as previous discussed), 
fermentable carbohydrates, and resistant starches, which are not 
broken down in the upper digestive tract (116). Fermentation of 
these substrates also results in the production of gases, including 
hydrogen, methane, and hydrogen sulfide.
In addition, the intestinal microbiota is involved in the activa-
tion/inactivation of bioactive food compounds, such as isoflava-
noid and plant lignans (112). In fact, a metabolic transformation, 
including deglycation and hydrolysis, is required for many plant 
polyphenols to induce their biologically active form. Within 
the colon, polyphenols are broken down by the microbiota to 
a variety of small phenolic components whose physiological 
relevance is not yet fully known (117). In addition, recent studies 
demonstrated that microbiota composition could be selectively 
modulated by polyphenol (118). Therefore, the positive effects 
associated with polyphenols consumption (105, 119, 120) should 
not only be attributed to their bioactive metabolites but also to the 
modulation of the intestinal microbiota.
Microbiota is also able to convert prodrugs into their bioactive 
forms and to modify xenobiotics and bile acids with potential 
effects on the GI motility, secretion, and immune function (112). 
These effects are also due to bile acids contribution to the modula-
tion of microbiota composition (121). Among harmful products 
of protein fermentation, hydrogen sulfide might be relevant for 
compromising intestinal health. In fact, it can be converted to 
thiosulfate and further oxidized to tetrathionate during inflamma-
tion. This product supports the growth of tetrathionate utilizing 
pathogens, many of which have been associated with the intestinal 
symptoms of irritable bowel syndrome (IBS) patients (122).
The metabolic function of the microbiota can result in opposite 
effects based on the dietary content. Diets containing fermentable 
fibers increase SCFA-producing bacteria. The produced SCFAs 
in turn protect the epithelium by acting on the intestinal barrier. 
Specifically, these diets increase TJ protein production and TER 
and decrease permeability and bacterial translocation. SCFAs 
also stimulate IEC metabolism, turnover, and apoptosis (123). 
A similar effect can be described for diets enriched in probiotic 
bacteria. On the contrary, diets that favor growth of pathogenic 
or opportunistic bacteria (as with intake of milk fat) would have 
opposite effects, compromising barrier integrity by altering TJ 
proteins production and distribution, and decreasing TER. These 
effects finally result in increased barrier permeability boosting 
bacterial translocation (124).
IN VITRO AND IN VIVO MODeLS TO 
STUDY iNTeSTiNAL PeRMeABiLiTY
Gold standards to measure intestinal permeability are the meas-
urement of TER for in vitro study and the intestinal permeability 
test (IPT) for in vivo study (29). TER measurement is an easy-to-
perform technique to investigate both the functional expression 
and the regulation of TJs (69). To perform measurements, cells 
are cultured as monolayers on commercially available permeable 
filter supports. To better mimic the physiological epithelial cell 
layer filter, supports have been designed with different pore densi-
ties and pore diameters (125). The most frequently used cellular 
line to study intestinal permeability is Caco-2. This line derives 
from human epithelial colorectal adenocarcinoma cells (73, 81, 
107) and when cultured in appropriate conditions is able to create 
a monolayer of cells with a luminal and basolateral polariza-
tion. Apart from the measurement of TER, in vitro studies also 
included the evaluation of the effects of human biopsy extracts 
on permeability to fluorescein isothiocyanate (FITC)–dextran 
in confluent monolayers of Caco-2 cells. Furthermore, to assess 
high capacity size and charge selective pathway versus low 
capacity paracellular route the morphological measurements of 
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TJ components in mucosal biopsies and the polyethylene glycol 
(PEG) profiling were used (126). Moreover, the Ussing chamber 
technique provides a short-term intestine fragments culture 
that measure electrical and transport parameters of an intact 
polarized intestinal epithelium (127). Some concerns with this 
method are related to the limited viability and function of an ex 
vivo intestinal preparation and the number of measurements that 
seem to be under representative for the physiological complexity 
of the intestinal mucosa (128).
For in  vivo models of intestinal permeability, IPT directly 
measures the ability of two non-metabolized sugar molecules 
(lactulose and mannitol) to permeate the intestinal mucosa (129, 
130). The degree of intestinal permeability is expressed by the 
levels of these two sugars recovered in a urine sample collected 
over the next 6 h (127). In fact, in case of barrier function loss 
these molecules cross the intestinal barrier, enter into the circula-
tion and can be detected in urine after renal excretion. IPT can 
discriminate between paracellular (lactulose) and transcellular 
(mannitol) pathways in  vivo, and it is a useful test in clinical 
studies because it gives information on the overall status of the 
intestine (villous atrophy and inflammation) (29). For research 
purpose, to study intestinal permeability in  vivo, experimental 
animal models can be used. It is possible to test the presence of 
macromolecular tracers (dextrans or Evans Blue) in the blood 
after gavage (29). But with this procedure, several parameters that 
significantly affect the measurement of intestinal permeability, 
such as gastrointestinal (GI) motility affecting the time of contact 
of the tracer with the mucosa and body distribution of the tracers, 
are not be taken into account. For this reason, to measure intes-
tinal permeability in animal models, intestinal loop systems and 
tracer recovery in mesenteric or portal blood could be preferred 
even if they require longer and more invasive procedures (131).
FOOD ReGULATiON OF iNTeSTiNAL 
iNFLAMMATiON: COOPeRATiON 
BeTweeN DieT, iMMUNe SYSTeM, AND 
MiCROBiOTA
Together with the IECs, there are at least two other important 
components to be taken into account for the regulation of intes-
tinal permeability: one internal and one external. The intestinal 
immune system accounts for the internal side of the barrier, 
while the microbiota represents the external one (132). Intestinal 
immunity is characterized by numerous dynamic responses that 
contribute to maintain the delicate balance between the capacity 
of mounting protective immune responses against infectious 
agents and the ability to tolerate innocuous antigens present in 
the intestinal lumen (133). The intestinal barrier is not completely 
impermeable to macromolecules. In fact, in the steady state, 
the transepithelial passage of small amounts of food-derived 
antigens and microorganisms participates in the induction of the 
homeostatic/tolerogenic immune response toward food antigens 
and commensal bacteria (12, 134). The mucosal immune system 
of the GI tract is composed of distinct immune cell types, such 
as neutrophils, monocyte/macrophages, DCs, mast cells, innate 
lymphoid cells, B, and T cells (135). The intestinal immune system 
regulates mucosal barrier function by different mechanisms: 
the modulation of epithelial dynamics, the regulation of AMPs 
production, the influence on the microbiota, and the induction 
of a response against microorganisms and luminal antigens that 
cross the barrier (13). Cytokines secreted by immune cells have 
been described as mediators involved in the regulation of mucosal 
barrier function at various levels, including the epithelial integ-
rity and the immune response (136, 137). For example, TNFα, 
among the major players involved in the inflammatory process, 
augments paracellular permeability by removing claudin 1 from 
TJs, increasing claudin 2 expression, and enhancing occludin 
degradation (138). The inflammatory response can also be modu-
lated by some amino acids. Taurine, one of the most abundant 
free amino acid in mammals, exerts anti-inflammatory functions 
both in vivo and in vitro (139, 140). The effects are mediated by 
taurine transporters (TAUT) whose synthesis and activity are 
increased in response to external stresses [e.g., osmotic pressure 
(141) and inflammatory cytokines (142, 143)] due to the necessity 
to maintain high intracellular level of this amino acid. Zhao et al. 
demonstrated that taurine supplementation reduces weight loss, 
diarrhea severity, colon shortening, and induces an increase in 
colonic tissue myeloperoxidase activity after DSS treatment (140). 
They also proved that taurine was able to inhibit the secretion 
of macrophage inflammation protein-2 (MIP-2) from IECs and 
the infiltration of inflammatory cells, such as neutrophils (140). 
Furthermore, several plant-derived polyphenols have been 
described as modulators of the inflammatory response (82, 119, 
120, 144). Their effect is likely mediated by the selective suppres-
sion of the inflammatory response of intestinal DCs. Possibly, 
the DCs mostly affected by the polyphenol exposure are those 
projecting dendrites into the intestinal lumen (33–35) where 
these compounds are more abundant.
The microbiota greatly influences mucosal barrier function 
both by direct and indirect modulation of the epithelial layer 
and mucosal components (145, 146). Specifically, a role in the 
regulation of intestinal permeability must be considered for some 
important microbiota components, i.e., probiotics and prebiotics. 
Probiotics are defined by the World Health Organization as “live 
organisms which, when administered in adequate amounts, confer 
a health benefit on the host” (147). Probiotics are non-pathogenic 
bacteria that are derived from the alimentary tract and are able to 
improve host colonic microenvironment (123). The precise pro-
biotics mechanism of action has yet to be fully clarified. Potential 
mechanisms on the epithelial barrier include a limited bacterial 
movement across the mucus layer through increasing mucin 
expression and secretion by goblet cells, an increased production 
of AMPs, and an enhanced TJs stability. Overall, these mechanisms 
reduce epithelial permeability to intraluminal pathogens and tox-
ins (148). Furthermore, probiotics influence mucosal immunity 
by increasing levels of IgA-producing cells in the lamina propria 
and promoting secretion of sIgA into the luminal mucus layers 
avoiding bacteria colonization of the epithelium (148). Through 
a cascade of signaling events, probiotics enhance the production 
and secretion of anti-inflammatory cytokines, including IL-10 
and transforming growth factor β (TGFβ) by T Regs (117). In 
small animal models, several reports have suggested that probiot-
ics enhance the local and systemic immune system through an 
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increased activity of IgA, T-cells, macrophages, T helper1 (Th1)-
cytokines, as well as the modulation of gut-associated lymphoid 
tissue, and natural killer cell cytotoxicity (149). Probiotics might 
also affect the intestinal microbiota and hence limit intestinal bac-
teria overgrowth and the production of lipopolysaccharides (123).
The beneficial effects of probiotics have been reported in 
several situations, such as food allergies (150), immune disor-
ders (151), prevention of intestinal tumors (152), prevention 
of body weight loss in animal models (153), and IBD (154). In 
fact, probiotics have gained big interest during the last decade 
as treatments to maintain intestinal homeostasis and reduce 
specific GI symptoms (155). Although it has been demonstrated 
that the use of probiotics in humans is relatively safe, some studies 
have questioned about the administration of a huge quantity of 
bacteria into a host (156). To avoid this potential risk, instead 
of using the whole live microorganisms, only probiotic-derived 
beneficial molecules have been administered. For example, a 
recombinant 40 kDa soluble protein derived from Lactobacillus 
rhamnosus GG (LGG) was able to reproduce the antiapoptotic 
effect of the bacterium in vitro (157). Importantly, the delivery of 
LGGp40 to the colon in vivo using a pectin/zein hydrogel bead 
system was able to ameliorate DSS-induced intestinal injury as 
well as oxazolone-induced Th2-driven colitis (157).
On the other hand, prebiotics are non-digestible food compo-
nents that contribute to host health by inducing specific changes 
in the composition and in the activity of intestinal microflora 
(158). They are fermented oligosaccharides, such as fructooligo-
saccharides, galactooligosaccharides, lactulose, and inulin, which 
stimulate the growth of beneficial gut bacteria (159). Due to their 
composition, they can only be absorbed in the colon, where they 
ferment into SCFAs and lactate (160), which are crucial energy 
sources for the host (161). The efficacy of prebiotics in IBD has 
been studied in  vitro (162) and in animal models (DSS- and 
TNBS-induced colitis) (163, 164). However, there are few human 
studies limited by a small number of patients (165). For example, 
in a recent study, UC patients were treated with mesalazine and 
randomly assigned to receive either oligofructose-enriched inu-
lin or placebo. Authors showed that the supplemented groups had 
lower fecal calprotectin than controls. As fecal calprotectin is an 
inflammatory marker, they concluded that prebiotics can reduce 
inflammation in UC patients (166).
Since probiotics are becoming a new therapeutic option, it is 
necessary to determine which strains have the greatest efficacy, if 
they are more effective alone or in conjunction with other pro or 
prebiotics, and what is their half-life in the GI tract. In fact, it is 
likely that a combined treatment with probiotics and prebiotics, 
called synbiotic therapy, can have a stronger effect on intestinal 
diseases than probiotics or prebiotics alone (123). It is also likely 
that the probiotic, prebiotic, or synbiotic combination will not 
be suitable for all patients, but the treatment will depend on the 
individual microbiota composition (123).
In agreement with the effect of the microbiota on the intes-
tinal permeability, a novel treatment option for IBD has gained 
interest, i.e., fecal microbiota transplantation (FMT) (167). Fecal 
transplantation (or bacteriotherapy) is the transfer of stool from 
a healthy donor into the GI tract of a patient. This strategy has 
been originally designed for the treatment of recurrent C. difficile 
colitis (168). C. difficile colitis is a complication of antibiotic 
therapy that may be associated with diarrhea, abdominal cramp-
ing, and sometimes fever (168). FMT appears to be the most 
effective intervention available for refractory C. difficile infection 
(rCDI). In fact, metronidazole, vancomycin, and fidaxomycin 
(antibiotics used for the treatment of this infection), fail in 
30% of treated individuals, causing a relapse of the infection 
(168). This was clearly demonstrated by an important paper 
describing a clinical trial that used FMT for rCDI (169). A total 
of 120 patients were enrolled, and they were treated with fecal 
transplant or vancomycin. The trial was interrupted in advance 
due to the difference between the two groups. Indeed, fecal 
transplant was three to four times more effective in eradicating 
the infection compared to the antibiotic. Fecal infusions cured 
13 out of 16 patients (81%), whereas only 7 out of 26 patients 
(27%) treated with vancomycin obtained the same result (169). 
Thus, FMT has been shown to be effective in treating relapsing or 
rCDI, but practical barriers and safety concerns have limited its 
widespread use (170). The majority of reported FMT procedures 
have been performed with fresh stool suspensions from related 
donors using delivery by colonoscopy. The use of fresh donations 
requires prior identification and screening of a suitable donor, 
thus precluding the use of FMT in acute situations (170). Donor 
selection is a crucial aspect for FMT. In fact, higher compliance 
has been reported if FMT is allowed from a donor chosen by the 
patient. Nonetheless, donations from healthy volunteer donors 
obtained by an unbiased selection resulted in lower incidence of 
viral infections and better genetics of the microbiota (171). In 
fact, it has been reported the case of a woman successfully treated 
with FMT with stools from a healthy but overweight donor that, 
later, developed new-onset obesity. The link between obesity and 
FMT transplant could be the result of multiple factors, including 
the resolution of CDI with subsequent increased appetite and 
the concurrent treatment of Helicobacter pylori. Nonetheless, the 
same has been observed in animal models that acquired an obese 
phenotype following the transplant of the microbiota from an 
obese donor (172). Furthermore, it is likely that the weight gain 
in the case reported was influenced by a combination of genetic 
factors derived from the donor and recipient microbiota (173).
It was recently described the successful use of frozen FMT 
inocula for the treatment of CDI. Carefully screened healthy 
volunteer donors were used to create capsules that prevent the 
need for invasive procedures for FMT administration, avoid 
procedure-associated complications, and significantly reduce 
the cost of the treatment (170). The major limitation of this 
study is the small sample size, the lack of placebo or active com-
parator, and the short follow-up that precludes the assessment of 
long-term immunological effects and onset of latent infections 
(170). Currently, several aspects limit the scientific value of the 
described protocol; nonetheless, it is a groundbreaking trial that 
will hopefully be validated in the near future.
Results from these analyses suggest that FMT is generally 
tolerable and safe. In fact, symptoms, such as a predominantly 
self-limiting fever, can be considered a consequence of the 
administration procedures themselves. Rigorous screening of 
the donor and donor stool remains particularly important to 
implement FMT efficacy (167). The approach to FMT in IBD is 
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still in its infancy, and much work remains to be done in order 
to clarify its ultimate utility. After all, the most efficient FMT 
delivery strategy and frequency, as well as the definition of an 
exact mix of prebiotics and probiotics to be transplanted remains 
to be further investigated (167).
CONCLUDiNG ReMARKS
Increased intestinal permeability can be related to different mech-
anisms; the opening of pores in the tight junctional complexes, an 
increased rate of transcytosis of antigens or ICs, the final stage of 
inflammation, apoptosis, and ulceration. All of these mechanisms 
cause the entry of luminal antigens into the lamina propria lead-
ing to the initiation of inflammatory immune responses that, 
if protracted, could become a chronic intestinal inflammatory 
syndrome. Indeed, a common feature of the intestinal diseases 
is the failure to contain the luminal content. Paracellular or 
transcellular pathways lead to chronic inflammation if not cor-
rectly regulated. Although the majority of dietary proteins are 
totally degraded by digestive enzymes and are absorbed in the 
form of nutrients, some can resist both the low pH of the gastric 
fluid and proteolytic enzyme hydrolysis. This means that large 
immunogenic peptides or intact proteins are capable of reaching 
the intestinal lumen by the different pathways described before. 
Intestinal barrier function is regulated by multiple components. 
Among these, an emerging role is depicted for nutrition. The role 
of different dietary antigens in the regulation of intestinal perme-
ability is in part contradictory. While some compounds such as 
gliadin impair the TJ barrier ultimately leading to CD, others 
such as Gln and polyphenols enhance and protect TJ barrier 
integrity. The latter category of food could be used as therapeutic 
tools for diseases associated with barrier defects. The effects of 
dietary compounds as preventive or therapeutic agents in dif-
ferent intestinal diseases have to be studied taking into account 
the complexity of the intestinal environment. The integrity of the 
epithelial cell monolayer is one of the players involved, and, at 
the moment, we still largely ignore whether barrier defects are 
the trigger or the effect of chronic inflammatory syndromes. A 
further level of complexity is determined by the variety of modi-
fications that change the chemical structure of the nutritionally 
derived compounds along the way through the intestine.
Composition of dietary intake can have significant impact 
on the microbiota, and consequently on the epithelial barrier. 
Considering bacteria fermentation, diets enriched in milk fat 
can promote the increase in barrier permeability and bacterial 
translocation along with the decrease in TJ proteins and TER. 
On the contrary, diets, including probiotic bacterial species or 
prebiotic fibers, strengthen the epithelial barrier by increasing 
TJ proteins and TER and decreasing permeability and bacterial 
translocation, thus, preventing or ameliorating the inflammatory 
state. It remains to be determined by the link between nutrition 
and microbiota composition. This is a challenging task as the 
influence of factors, such as genetics, hygiene, and living condi-
tions, are not taken into account in studies comparing distinct 
populations.
Understanding the intricate relationship between epithelial 
barrier, microbiota, and diet will contribute to design new 
preventive/therapeutic approaches for GI diseases, particularly 
IBD. This is becoming in part true if we consider the use of 
fecal therapy instead of classical antibiotics treatment for rCDI. 
Nonetheless, this new therapeutic approach needs to be further 
investigated, in particular, for the definition of precise parameters 
for the donor choice.
Deep analysis of the microbiota is now possible due to faster 
sequencing techniques and improved bioinformatics tools 
even if the major challenge remains the ability to discriminate 
between healthy and disease microbiota state. In fact, substantial 
inter- and intra-individual variations in addition to age-related 
changes in the composition of the intestinal microbiota were 
identified providing an additional level of complexity to this 
intricate pattern.
In the recent years, the challenge for the human race was to 
obtain enough food to provide sufficient nutrients to the body. 
Nowadays, in vast regions of the planet, the challenge is to sustain 
the body with the right combination of nutrients able to prevent 
chronic inflammatory syndromes. We knew the importance of 
the intestinal permeability, we then realized the importance of 
the cross talk between the intestinal epithelium and the immune 
system, and we are just starting to realize the pivotal role of the 
microbiota for human health. A further level of complexity will 
need to be addressed in the near future; in particular, we will 
need to understand the cascade of events that lead to chronic 
inflammatory syndromes. In vitro studies are still required to dis-
sect the effects of single nutritional components as well as their 
effects when combined. Animal models will be required to better 
understand the effects of nutritional strategies for the prevention/
treatment of chronic inflammatory syndromes. We still need to 
shed light on the axis between microbial communities and the 
nutritional intake as well as on the axis between microbial com-
munities and post-modifications of the nutritional compounds. 
These modifications may severely impact the biological effects 
of the nutrients. Finally, in light of what was discovered by 
Fonseca and others (174), trials based on food components as 
complementary approach, should consider a working hypothesis 
made of three consecutive steps. The first should be an antibiotic 
approach to eliminate the pre-existing microbiota, the second 
should be the administration of a selected mix of prebiotics and 
probiotics to create a known microbiota, and then, the final step 
should be the nutritional intervention.
The switch from acute to chronic disease characterized the 
last century. Health systems are still adjusting to the need for 
long term and personalized medicine that will consider nutrition 
much more than just food intake.
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